1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Therapies and Diagnostics for Uterine Cancer

Therapies and Diagnostics for Uterine Cancer

  • September 2013
  • -
  • BCC Research
  • -
  • 169 pages

STUDY GOALS AND OBJECTIVES

This report HLC142A Therapies and Diagnostics for Uterine Cancer provides an overview of the current and potential global market for uterine cancer, treatments, screening and testing technologies. The report provides comprehensive information on uterine cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global uterine cancer therapeutics market. The key objective is to present a comprehensive analysis of current uterine cancer technology and the utilization of the various therapeutic, screening and diagnostic modalities. The report’s focus is on uterine disorders, current treatment strategies and drugs, chemotherapy and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments and sales forecasts by treatment and screening categories from 2013 through 2018 are provided. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the uterine cancer market.
It also focuses on the treatment usage patterns in the global uterine cancer therapeutics market, competitive landscape, and the emerging players and pipeline products. The report also details opportunities for future players.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information on testing and treatment options for uterine disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of endometrial disorders and related cancers.
This BCC market research report will increase the reader’s awareness of current and emerging drugs and technologies for uterine cancers, therapeutics, chemotherapy and surgical therapy.

INTENDED AUDIENCE

This report is a detailed study on the global uterine cancer market, with key statistics and analysis of current drugs and screening and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in uterine cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of uterine cancer products and services. This study will be largely of interest to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the relative sector. This report discusses tests currently being used for uterine disorders, cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, uterine cancer diagnostic tests in use and future growth.

SCOPE OF THE STUDY

The scope of this study is diagnostic test and therapeutic markets for uterine cancers. Screening tests are included as discussion only, as new studies have reflected that Pap smears, CT scans and ultrasound could be used as screening aids for uterine cancer. The exact usage for these tests for uterine cancer is still under research; therefore, sales numbers and revenue forecasts from this segment are not included in the final market summary. The focus of this report is on diagnostic tests and therapeutics for uterine cancer, including surgery and diagnostic methods (e.g., hysteroscopy and endometrial biopsy) that are currently in use. The report also includes discussions on the current technologies, new technologies, incidence, market projections and market share, along with the latest trends and new developments.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of uterine cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on uterine cancer and disorders, products, global incidence and drug development was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within academia, industry and the medical community, and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

REPORT HIGHLIGHTS

This report provides:
• An overview of the global market for diagnostics and therapies for uterine cancer
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• A breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy
• Discussion of uterine cancer biology
• Delineation of drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic
• Evaluation of the patent landscape
• Comprehensive profiles of key companies.

Table Of Contents

Therapies and Diagnostics for Uterine Cancer
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ABOUT THE AUTHOR 4
RELATED BCC REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 7

SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND
DIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8
SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND
DIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9

CHAPTER 3 OVERVIEW 11

GYNECOLOGIC CANCERS 11
CANCER 11
TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 12
ENDOMETRIAL/UTERINE CANCER 13
TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER 13
TABLE 3 HISTOLOGY OF ADENOCARCINOMA 15
CAUSES/RISK FACTORS 15
Hormone Factors 16
TABLE 4 RISK FACTORS 16
Estrogen 17
Estrogen Therapy 17
Oral Contraceptives 17
Total Number of Menstrual Cycles 17
Pregnancy 17
Obesity 18
Treatment with Tamoxifen 18
Ovarian Tumors 18
Polycystic Ovarian Syndrome 18
Use of an Intrauterine Device 19
Age 19
Diet and Exercise 19
Diabetes 19
Genetics 19
TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 20
Breast Cancer 20
Prior Pelvic Radiation Therapy 20
Endometrial Hyperplasia 20
CLASSIFICATION 20
Carcinoma 20
TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC
GROUPS 21
Sarcoma 21
TABLE 7 CARCINOMA OF THE ENDOMETRIUM 22
ENDOMETRIAL CANCER SYMPTOMS 22
TABLE 8 SIGNS AND SYMPTOMS 23
DIAGNOSIS 23
Clinical Evaluation 23
TABLE 9 UTERINE CANCER: DIAGNOSIS 24
Tests 24
TABLE 10 DIAGNOSTIC TESTS 24
TABLE 11 STAGES OF ENDOMETRIAL CANCER 25
Pathology 25
TREATMENT 26
TABLE 12 TREATMENT DEPENDS UPON THE STAGE 26
Uterine Cancer Treatment is Based on Several Important Factors 27
PROGNOSIS 28
Survival Rates 28
TABLE 13 FIVE-YEAR SURVIVAL RATES (%) 29
TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 29
EPIDEMIOLOGY 30
COMPLICATIONS 30
PREVENTION 30

CHAPTER 4 UTERINE CANCER: BIOLOGY 32

UTERUS AND ENDOMETRIUM 32
UTERINE CANCER 32
TABLE 15 TYPES OF UTERINE CANCERS 33
CLINICAL PRESENTATION 33
ESTROGEN'S ROLE 34
TYPES OF ENDOMETRIAL CANCER 34
Carcinoma 34
Type I Endometrial Carcinoma 34
Type II Endometrial Carcinoma 35
Endometrioid Cancer: Grade 35
TABLE 16 GRADING 35
Uterine Sarcomas 36
TUMOR MARKERS 36
Types of Gynecologic Tumor Markers 37
TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS 37
TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS 37
Clinical Usefulness of Tumor Markers 38
Expression of L1CAM Protein Predicts Recurrence of Endometrial
Cancer 38
GENOMIC CLASSIFICATION OF ENDOMETRIAL CANCERS 39
Treatment Planning Based on Genomic Information: Advantages 39
Study Details 40
Summary/Key Facts from the Study 41
TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS 42
CONCLUSIONS 42

CHAPTER 5 UTERINE CANCER DIAGNOSIS AND SCREENING 45

SCREENING FOR ENDOMETRIAL CANCER 45
CAN ENDOMETRIAL CANCER BE FOUND EARLY? 45
Early Detection Tests 46
STAGING 46
TABLE 20 STAGING OF UTERINE CANCER 46
SCREENING PROCEDURES 46
Low Endometrial Cancer Risk 46
High Endometrial Cancer Risk 47
Current Screening Methods 47
Endometrial Cancer Diagnosis 47
Clinical Evaluation 48
DIAGNOSTIC TESTS FOR ENDOMETRIAL CANCER 48
TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES 48
Dilatation and Curettage (DandC) 48
Pap Test 49
Transvaginal Ultrasound 49
Hydroultrasound 49
Endometrial Biopsy 50
Hysteroscopy 50
Other Lab Tests 50
Tumor Markers 50
Other Tests 51
Routine Blood Tests 51
New Test: GynEC-Dx 51
TABLE 22 GYNECDX KEY FEATURES 52

CHAPTER 6 UTERINE CANCER TREATMENT STRATEGIES 54

ENDOMETRIAL CANCER RESEARCH 54
HISTOPATHOLOGICAL CHARACTERISTICS 55
MOLECULAR PATHOLOGY OF ENDOMETRIAL CANCER 55
TUMOR MARKERS 55
TREATMENT STRATEGIES 56
SURGERY 56
Surgical Treatment in Stage I Endometrial Cancer 57
Surgical Treatment in Stage II Endometrial Cancer 57
Surgical Treatment in Stage III-IV Endometrial Cancer 57
Hysterectomy 57
TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED 58
Other Options to Hysterectomy 58
Nerve Block 58
Medication Therapy 59
Myomectomy 59
Ablation 59
Balloon Therapy 59
Hysterectomy Surgical Procedures 59
TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES 60
Radiation Therapy 60
Radiation Therapy for Endometrial Cancer 61
TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER 61
TABLE 26 RADIATION THERAPY: SIDE EFFECTS 61
Risks 62
TABLE 27 SIDE EFFECTS OF RADIATION 62
Chemotherapy 62
Combined Radiotherapy-Chemotherapy 63
Locoregional Recurrence 63
Advanced Disease 63
Treatment of Metastatic Disease and Relapse 64
Papillary Serous Carcinoma and Clear Cell Carcinoma 64
Hormone Therapy 65
NEW THERAPEUTICS IN DEVELOPMENT 66
TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS 66
TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER 68
TABLE 30 DRUGS IN THE PIPELINE 70
CONCLUSIONS 71

CHAPTER 7 UTERINE CANCER INCIDENCE 73

TABLE 31 KEY FACTS: CANCER 73
TABLE 32 PREVENTION STRATEGIES 75
EARLY DETECTION 75
SCREENING 75
TREATMENT 75
UTERINE CANCER GLOBAL INCIDENCE 76
TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008-2018 76
TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLD
AGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION 77
TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OF
UTERINE CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030 78
NORTHERN AMERICA 79
United States 79
TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY,
2011-2013 79
TABLE 37 KEY FINDINGS 80
INCIDENCE AND MORTALITY 81
Surveillance, Epidemiology and End Results (SEER) Incidence 81
TABLE 38 INCIDENCE RATES BY RACE 81
U.S. Mortality 81
TABLE 39 DEATH RATES BY RACE 82
SURVIVAL AND STAGE 82
TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES
BY STAGE AT DIAGNOSIS, 2003-2009 (%) 82
LIFETIME RISK 83
PREVALENCE 83
INTERVENTIONS ASSOCIATED WITH DECREASED RISK 83
Oral Contraceptives 83
Physical Activity 84
Increasing Parity and Lactation 84
INTERVENTIONS ASSOCIATED WITH INCREASED RISK 84
Endogenous Estrogen 84
Exogenous Estrogen: Postmenopausal Hormone Therapy (HT) 84
Combination Estrogen-Progestin Replacement Therapy 85
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen and
Raloxifene 85
Obesity 86
Increasing Age 86
Genetic Predisposition 86
INTERVENTIONS OF UNPROVEN OR DISPROVEN EFFECT ON RISK 86
Weight Loss 86
Fruits, Vegetables and Vitamins 87
EUROPE 87
Trends in Postmenopausal Women 88
Trends in Premenopausal Women 89
United Kingdom 90
TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEW
CASES, CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER
100,000 POPULATION, 2008
91
TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASES
AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000
POPULATION, 2008
91
INDIA 92

CHAPTER 8 GLOBAL MARKET FOR UTERINE CANCER TREATMENTS AND DIAGNOSTICS 94
CANCER: GLOBAL COSTS 94

CANCER IN THE UNITED STATES 95
TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020
(NUMBER%) 95
TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010
AND 2020 ($ MILLIONS/%) 96
TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND
2020 (NUMBER/%) 97
TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERS
BY TYPE, 2010 AND 2020 (NUMBER/%) 97
CURRENT ENDOMETRIAL CANCER SCREENING AND DIAGNOSIS 98
SCREENING 98
TABLE 47 CURRENT TESTS FOR UTERINE CANCER 98
DIAGNOSIS 98
GLOBAL MARKET FOR UTERINE CANCER DIAGNOSTIC TESTS 99
TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 99
FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 99
GLOBAL MARKET FOR ENDOMETRIAL SAMPLING 100
TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 101
FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:
SALES AND FORECAST 2012-2018 ($ MILLIONS) 101
Dilation and Curettage 101
GLOBAL MARKET FOR HYSTEROSCOPIES 102
TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 102
FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 102
U.S. Market for Hysteroscopies 103
TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, THROUGH 2018 ($ MILLIONS) 103
FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, 2012-2018 ($ MILLIONS) 103
Testing of Endometrial Tissue 104
GLOBAL PAP SMEAR TEST MARKET 104
TABLE 52 CURRENT CERVICAL CANCER SCREENING 105
TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET AND
FORECAST, THROUGH 2018 ($ MILLIONS) 106
FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET AND
FORECAST, 2012-2018 ($ MILLIONS) 106
U.S. PAP SMEAR MARKET 106
TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE,
2012 AND 2013 ($ MILLIONS) 107
TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 107
TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS,
AGE-STRATIFIED, 2008 AND 2010 108
TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010 108
TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S.,
2010 109
GLOBAL COST OF PAP SMEARS 109
LATEST TECHNOLOGY 109
GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUND 110
TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 112
FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 112
U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS 113
TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 113
FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 113
OTHER TESTS FOR ENDOMETRIAL CANCER 113
Cystoscopy and Proctoscopy 113
OTHER IMAGING TESTS 114
TABLE 61 IMAGING TESTS 114
Magnetic Resonance Imaging (MRI) 114
Positron Emission Tomography (PET) 115
Chest X-ray 115
Blood Tests 115
Complete Blood Count 115
GLOBAL MARKET FOR COMPUTED TOMOGRAPHY (CT) 115
TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE
CANCER: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 116
FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE
CANCER: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 116
U.S. MARKET FOR COMPUTED TOMOGRAPHY (CT) 116
TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES
AND FORECAST, THROUGH 2018 ($ MILLIONS) 117
FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES
AND FORECAST, 2012-2018 ($ MILLIONS) 117
GLOBAL CA-125 TEST MARKET 117
TABLE 64 ELEVATED CA-125 LEVEL 118
TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 119
FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 119
U.S. CA-125 TEST MARKET 119
TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 120
FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
2012-2018 ($ MILLIONS) 120
GENETIC TESTING 120
TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED 121
MOLECULAR DIAGNOSTICS 121
PAPGENE TEST 121
CONCLUSIONS 122

CHAPTER 9 TREATMENT MARKET 125

ENDOMETRIAL CANCER: CURRENT PRACTICES 125
TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISK
OF RELAPSE AFTER SURGERY 125
GLOBAL MARKET FOR ENDOMETRIAL CANCER TREATMENTS 126
TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY
APPLICATION TYPE, THROUGH 2018 ($ MILLIONS) 126
FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY
APPLICATION TYPE, 2012-2018 ($ MILLIONS) 126
GLOBAL MARKET FOR RADIATION THERAPY TO TREAT UTERINE CANCER 127
Vaginal Brachytherapy 127
TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY 127
External Beam Radiation Therapy 128
TABLE 71 SIDE EFFECTS OF RADIATION THERAPY 128
TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 129
FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 129
U.S. Market for Radiation Therapy to Treat Uterine Cancer 130
TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES
AND FORECAST, THROUGH 2018c ($ MILLIONS) 131
FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER
MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 131
CHEMOTHERAPY 132
TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY 132
GLOBAL UTERINE DRUG TREATMENT MARKET 132
TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH
2018 ($ MILLIONS) 133
GLOBAL MARKET FOR CYTOTOXIC THERAPIES 133
TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS 134
TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 ($ MILLIONS) 134
FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 ($ MILLIONS) 134
U.S. Market for Cytotoxic Therapies 135
TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 135
FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 135
European Market for Cytotoxic Therapies 135
TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 136
FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 136
Japanese Market for Cytotoxic Therapies 136
TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 137
FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 137
Drawbacks of Chemotherapy 137
Drugs Used in Chemotherapy 138
TABLE 81 DRUGS USED TO TREAT UTERINE CANCER 138
Paclitaxel 138
TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 ($ MILLIONS) 139
Carboplatin 139
TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS) 139
Cisplatin 139
Hycamtin 140
TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 ($ MILLIONS) 140
Avastin 140
TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 ($
MILLIONS) 141
Cisplatin + Paclitaxel 141
Depo-Provera 141
Megestrol + Tamoxifen 142
AEZS-108 142
Ixabepilone 142
Ridaforolimus (Deforolimus, AP23573) 143
SAR245408 (XL147) 145
HORMONE THERAPY FOR ENDOMETRIAL CANCER 145
Progestins 145
Tamoxifen 145
Gonadotropin-releasing Hormone Agonists 145
Aromatase Inhibitors 146
UTERINE CANCER MARKET AND CHINA 146
UTERINE CANCER MARKET AND INDIA 146
Hysterectomies in India 146
TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS IN
THE U.S., 2012 ($) 147
ENDOMETRIAL CANCER IN YOUNG WOMEN 147
CANCER IN THE OBESE PATIENT OR MEDICALLY INOPERABLE WOMAN 147
INCOMPLETELY STAGED PATIENTS 147
TREATING MENOPAUSAL SYMPTOMS 148
SURGICAL TREATMENTS OF ENDOMETRIAL CANCER 148
Incidence of Hysterectomy 148
TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY
WORLDWIDE 148
TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
NORTH AMERICA 149
TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
CENTRAL AMERICA 149
TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
SOUTH AMERICA, 150
TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
EUROPE 150
TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
ASIA 151
TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
THE MIDDLE EAST 152
TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
NORTHERN AFRICA 152
TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
THE OCEANIA REGION 153
Robotic Surgery 154
TABLE 96 HYSTERECTOMY FACTS 155
da Vinci System 155
Incidence of Hysterectomy in the United Kingdom 156
Global Incidence of Hysterectomy 156
TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMED
ANNUALLY BY TYPE 156
UTERINE CANCER SURGERY MARKET 157
Revenues from Hysterectomies 157
TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BY
TYPE, 2013 ($ MILLIONS) 157
TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMY
PROCEDURES PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES 157
TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALES
AND FORECAST, 2013 ($ MILLIONS) 158
TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES
AND FORECAST, 2013 ($ MILLIONS) 158
TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND
FORECAST 2013 ($ MILLIONS) 159
Revenues from Hysterectomies by Type 159
TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159
FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 159
U.S. Revenues from Hysterectomies by Type 160
TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 160
FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2011-2018 160
Hysterectomies in India 161
ALTERNATE THERAPIES 161
Uterine Balloon Therapy 161
Myomectomy 161
Transcervical Resection of Endometrium (TCRE) 162
Hysteroscopic Polypectomy 162
Mirena (Hormone Loaded Intrauterine Device) 162
Agonadotropin-Releasing Hormone Agonist (GnRH Agonist) 162
Uterine Artery Embolization (UAE) 163
MRI Guided Focused Ultrasound 163
CT Scan 163
CONCLUSION 163

CHAPTER 10 PATENT LANDSCAPE 166

GLOBAL IMPACT OF PATENT EXPIRIES 166
PATENT LANDSCAPE 166
HYCAMTIN (TOPOTECAN HYDROCHLORIDE) 167
TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS 167
CISPLATIN 168
AVASTIN 168

CHAPTER 11 SELECTED COMPANY PROFILES 170

ABBOTT LABORATORIES 170
AETERNA ZENTARIS INC. 170
ASTRAZENECA 170
BECTON, DICKINSON AND CO. 171
BRISTOL-MYERS SQUIBB 171
EXELIXIS 171
FEMASYS 172
GLAXOSMITHKLINE 172
INTUITIVE SURGICAL 172
JOHNSON and JOHNSON 172
MERCK 173
ORYZON GENOMICS 173
PFIZER 174
QIAGEN 174
QUEST DIAGNOSTICS 175
RJ MADRID 175
ROCHE DIAGNOSTICS 176
SANOFI 176
SIEMENS AG 176
TAJ PHARMACEUTICALS 176
TEVA PHARMACEUTICAL INDUSTRIES 177
VARIAN MEDICAL SYSTEMS 177

CHAPTER 12 BIBLIOGRAPHY 179



LIST OF TABLES

SUMMARY TABLE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,
GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8
TABLE 1 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 12
TABLE 2 KEY CLINICAL FEATURES OF UTERINE CANCER 13
TABLE 3 HISTOLOGY OF ADENOCARCINOMA 15
TABLE 4 RISK FACTORS 16
TABLE 5 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 20
TABLE 6 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC
GROUPS 21
TABLE 7 CARCINOMA OF THE ENDOMETRIUM 22
TABLE 8 SIGNS AND SYMPTOMS 23
TABLE 9 UTERINE CANCER: DIAGNOSIS 24
TABLE 10 DIAGNOSTIC TESTS 24
TABLE 11 STAGES OF ENDOMETRIAL CANCER 25
TABLE 12 TREATMENT DEPENDS UPON THE STAGE 26
TABLE 13 FIVE-YEAR SURVIVAL RATES (%) 29
TABLE 14 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 29
TABLE 15 TYPES OF UTERINE CANCERS 33
TABLE 16 GRADING 35
TABLE 17 IMPORTANT GYNECOLOGIC TUMOR MARKERS 37
TABLE 18 POTENTIAL GYNECOLOGIC TUMOR MARKERS 37
TABLE 19 UTERINE CANCER GENOMIC SUBTYPES: KEY CHARACTERISTICS 42
TABLE 20 STAGING OF UTERINE CANCER 46
TABLE 21 UTERINE CANCER SCREENING TESTS OR PROCEDURES 48
TABLE 22 GYNECDX KEY FEATURES 52
TABLE 23 CONDITIONS UNDER WHICH HYSTERECTOMY IS PERFORMED 58
TABLE 24 TYPES OF HYSTERECTOMY PROCEDURES 60
TABLE 25 TWO TYPES OF RADIATION THERAPY TO TREAT ENDOMETRIAL CANCER 61
TABLE 26 RADIATION THERAPY: SIDE EFFECTS 61
TABLE 27 SIDE EFFECTS OF RADIATION 62
TABLE 28 DRUGS CURRENTLY IN USE TO TREAT UTERINE CANCERS 66
TABLE 29 COMBINATION PRODUCTS USED FOR TREATING UTERINE CANCER 68
TABLE 30 DRUGS IN THE PIPELINE 70
TABLE 31 KEY FACTS: CANCER 73
TABLE 32 PREVENTION STRATEGIES 75
TABLE 33 GLOBAL INCIDENCE OF UTERINE CANCER, 2008-2018 76
TABLE 34 GLOBAL CORPUS UTERINE CANCER (C54) 2008 ESTIMATES: WORLD
AGE-STANDARDIZED INCIDENCE RATES PER 100,000 WOMEN BY REGION 77
TABLE 35 UNITED KINGDOM: AGE-STANDARDIZED RATES AND NUMBER OF UTERINE
CANCER DIAGNOSES PER 100,000 WOMEN, 2007 AND 2030 78
TABLE 36 UNITED STATES: UTERINE CANCER INCIDENCE AND MORTALITY,
2011-2013 79
TABLE 37 KEY FINDINGS 80
TABLE 38 INCIDENCE RATES BY RACE 81
TABLE 39 DEATH RATES BY RACE 82
TABLE 40 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES
BY STAGE AT DIAGNOSIS, 2003-2009 (%) 82
TABLE 41 UNITED KINGDOM UTERINE CANCER INCIDENCE, NUMBER OF NEW CASES,
CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000
POPULATION, 2008
91
TABLE 42 UNITED KINGDOM: GYNECOLOGICAL CANCERS, NUMBER OF NEW CASES
AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000
POPULATION, 2008
91
TABLE 43 UNITED STATES: NUMBER OF CANCER SURVIVORS, 2010 AND 2020
(NUMBER%) 95
TABLE 44 UNITED STATES: PROJECTED COST OF UTERINE CANCER CARE, 2010 AND
2020 ($ MILLIONS/%) 96
TABLE 45 UNITED STATES: NUMBER OF UTERINE CANCER SURVIVORS, 2010 AND
2020 (NUMBER/%) 97
TABLE 46 UNITED STATES: NUMBER OF SURVIVORS OF GYNECOLOGICAL CANCERS
BY TYPE, 2010 AND 2020 (NUMBER/%) 97
TABLE 47 CURRENT TESTS FOR UTERINE CANCER 98
TABLE 48 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 99
TABLE 49 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 101
TABLE 50 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 102
TABLE 51 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, THROUGH 2018 ($ MILLIONS) 103
TABLE 52 CURRENT CERVICAL CANCER SCREENING 105
TABLE 53 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST, MARKET AND
FORECAST, THROUGH 2018 ($ MILLIONS) 106
TABLE 54 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE,
2012 AND 2013 ($ MILLIONS) 107
TABLE 55 U.S.: PERCENTAGE OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 107
TABLE 56 U.S.: PERCENTAGE OF WOMEN WHO RECEIVE PAP SMEAR TESTS,
AGE-STRATIFIED, 2008 AND 2010 108
TABLE 57 PAP TESTS ORDERED OR PROVIDED IN THE U.S., 2010 108
TABLE 58 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT VISITS IN THE U.S.,
2010 109
TABLE 59 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 112
TABLE 60 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 113
TABLE 61 IMAGING TESTS 114
TABLE 62 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE
CANCER: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 116
TABLE 63 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES
AND FORECAST, THROUGH 2018 ($ MILLIONS) 117
TABLE 64 ELEVATED CA-125 LEVEL 118
TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 119
TABLE 66 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 120
TABLE 67 GENETIC COUNSELING MAY BE RECOMMENDED 121
TABLE 68 SEVERAL RECOGNIZED PATHOLOGIC AND CLINICAL FACTORS FOR RISK
OF RELAPSE AFTER SURGERY 125
TABLE 69 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY
APPLICATION TYPE, THROUGH 2018 ($ MILLIONS) 126
TABLE 70 TYPES OF VAGINAL BRACHYTHERAPY 127
TABLE 71 SIDE EFFECTS OF RADIATION THERAPY 128
TABLE 72 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 129
TABLE 73 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER: SALES
AND FORECAST, THROUGH 2018C ($ MILLIONS) 131
TABLE 74 COMMON SIDE EFFECTS OF CHEMOTHERAPY 132
TABLE 75 GLOBAL MARKET FOR DRUGS TO TREAT UTERINE CANCER, THROUGH
2018 ($ MILLIONS) 133
TABLE 76 CYTOTOXIC THERAPIES: INDICATIONS 134
TABLE 77 GLOBAL CYTOTOXIC MARKET, 2010 AND 2017 ($ MILLIONS) 134
TABLE 78 U.S. CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 135
TABLE 79 EUROPEAN CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 136
TABLE 80 JAPANESE CYTOTOXIC THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 137
TABLE 81 DRUGS USED TO TREAT UTERINE CANCER 138
TABLE 82 UTERINE CANCER: CISPLATIN SALES, 2010 ($ MILLIONS) 139
TABLE 83 UTERINE CANCER: CARBOPLATIN SALES, 2010-2012 ($ MILLIONS) 139
TABLE 84 UTERINE CANCER: HYCAMTIN SALES, 2010-2012 ($ MILLIONS) 140
TABLE 85 UTERINE CANCER: AVASTIN SALES AND FORECAST, THROUGH 2018 ($
MILLIONS) 141
TABLE 86 COSTS OF A HYSTERECTOMY IN INDIA COMPARED WITH THE COSTS IN
THE U.S., 2012 ($) 147
TABLE 87 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY
WORLDWIDE 148
TABLE 88 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
NORTH AMERICA 149
TABLE 89 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
CENTRAL AMERICA 149
TABLE 90 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
SOUTH AMERICA, 150
TABLE 91 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
EUROPE 150
TABLE 92 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
ASIA 151
TABLE 93 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE
MIDDLE EAST 152
TABLE 94 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN
NORTHERN AFRICA 152
TABLE 95 ESTIMATED NUMBER OF HYSTERECTOMIES PERFORMED ANNUALLY IN THE
OCEANIA REGION 153
TABLE 96 HYSTERECTOMY FACTS 155
TABLE 97 GLOBAL ESTIMATES OF THE NUMBER OF HYSTERECTOMIES PERFORMED
ANNUALLY BY TYPE 156
TABLE 98 ESTIMATED GLOBAL REVENUES FROM HYSTERECTOMY PROCEDURES BY
TYPE, 2013 ($ MILLIONS) 157
TABLE 99 UNITED STATES AND CANADA: NUMBER OF HYSTERECTOMY PROCEDURES
PERFORMED ANNUALLY BY TYPE, 2013 ESTIMATES 157
TABLE 100 UNITED STATES AND CANADA: HYSTERECTOMY PROCEDURES: SALES
AND FORECAST, 2013 ($ MILLIONS) 158
TABLE 101 KEY EUROPEAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND
FORECAST, 2013 ($ MILLIONS) 158
TABLE 102 KEY ASIAN COUNTRIES: HYSTERECTOMY PROCEDURES: SALES AND
FORECAST 2013 ($ MILLIONS) 159
TABLE 103 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159
TABLE 104 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, THROUGH 2018 ($ MILLIONS) 160
TABLE 105 PATENT EXPIRIES ON CANCER CHEMOTHERAPY DRUGS 167



LIST OF FIGURES

SUMMARY FIGURE UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,
GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9
FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC TESTS: MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 99
FIGURE 2 GLOBAL MARKET FOR ENDOMETRIAL BIOPSY FOR UTERINE CANCER:
SALES AND FORECAST 2012-2018 ($ MILLIONS) 101
FIGURE 3 GLOBAL MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 102
FIGURE 4 U.S. MARKET FOR HYSTEROSCOPIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, 2012-2018 ($ MILLIONS) 103
FIGURE 5 GLOBAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TEST MARKET AND
FORECAST, 2012-2018 ($ MILLIONS) 106
FIGURE 6 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 112
FIGURE 7 U.S. MARKET FOR TRANSVAGINAL ULTRASOUNDS: SALES AND FORECAST,
2012-2018 ($ MILLIONS) 113
FIGURE 8 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR UTERINE
CANCER: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 116
FIGURE 9 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALES
AND FORECAST, 2012-2018 ($ MILLIONS) 117
FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
2012-2018 ($ MILLIONS) 119
FIGURE 11 U.S. DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES AND FORECAST,
2012-2018 ($ MILLIONS) 120
FIGURE 12 GLOBAL ENDOMETRIAL CANCER MARKET: SALES AND FORECAST BY
APPLICATION TYPE, 2012-2018 ($ MILLIONS) 126
FIGURE 13 GLOBAL MARKET FOR RADIATION USED TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 129
FIGURE 14 U.S. MARKET FOR RADIATION USED TO TREAT UTERINE CANCER MARKET:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 131
FIGURE 15 GLOBAL CYTOTOXIC THERAPY MARKET, 2010 AND 2017 ($ MILLIONS) 134
FIGURE 16 U.S. CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 135
FIGURE 17 EUROPEAN CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 136
FIGURE 18 JAPANESE CYTOTOXIC THERAPY MARKET, 2012-2018 ($ MILLIONS) 137
FIGURE 19 GLOBAL MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER:
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 159
FIGURE 20 U.S. MARKET FOR HYSTERECTOMIES TO TREAT UTERINE CANCER: SALES
AND FORECAST, 2011-2018 160

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.